You are here: Industry Insights > Hyundai Bioscience

News List

Hyundai Bioscience finds combination therapy effective against Covid-19 Pharmaceutical-Technology
December 09, 2021
Hyundai Bioscience has reported that a combination of the niclosamide-based oral antiviral drug candidate, CP-COV03, with anti-inflammatory therapy, dexamethasone, showed to be effective in people with severe Covid-19 in a study.
Hyundai Bioscience Develops Injection Drug for Potential Treatment of Severe Cases of COVID-19 prnasia
December 23, 2020
Hyundai Bioscience announced on the 23rd, December 2020, that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of COVID-19.
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem prnewswire
December 09, 2020
Hyundai Bioscience released a report on December 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single ...